RecipharmCobra Biologics and KAHR Medical Ltd. have agreed to continue to advance candidate KAHR-102 for future preclinical and clinical testing using RecipharmCobra’s maxXpress service.

KAHR develops novel drugs based on the Signal Converter Proteins (SCP) technology for the treatment of cancer and autoimmune diseases. The company has been collaborating with RecipharmCobra for four years. KAHR-102 is a fusion protein that is being investigated for use against autoimmune conditions such as psoriasis and rheumatoid arthritis.
 
Peter Coleman, general manager at RecipharmCobra Biologics, said, “We are extremely pleased that our development partnership continues with KAHR. Our partnership with KAHR has strengthened over the years due to the strong working relationship between both technical teams and we look forward to its continuation. It is an endorsement of the working relationship we invest in with our customers.”
 
Dr. Naom Shani, KAHR's chief executive officer, added, “It has been a pleasure working with RecipharmCobra Biologics over the years and we have enjoyed the interaction and responsiveness of its team. We hope to build on our successful partnership with the fast-track development of KAHR-102.”
 
RCB's maxXpress service combines cell line development with Ubiquitous Chromatin Opening Elements (UCOE) technology to get quicker, more efficient results than traditional gene amplification systems, according to the company.